Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let's not forget that the "confirmation" study was to confirm the results from the first study that went COUNTER to what they thought they were going to find. This tells us that the company didn't understand what they are doing initially, hence the totally opposite results (granted this is common in science) and that the CEO has no clue about the science as demonstrated in every concall where the fat bastard lying CEO had to have Harry explain what was going on. The funniest thing about the call is where the CEO is asking his paid consultant to explain to him what the results meant. David Konman Koos is a dumb KLOWN. The only thing he knows how to do is how to use the company as his personal ATM,
BTW, the CEO of oncofakeapharma pleaded guilty. Remember, this is the guy that Koos opted to do business with. I said at the time onph was dirty and we know now it as a fraudulent company run by another fraud. Corrupt birds of a feather flock together. The SEC needs to investigate David Conman Koos.
https://www.justice.gov/usao-ma/pr/former-stockbroker-pleads-guilty-penny-stock-securities-fraud-scheme
What other reputable or sinky pinky bio companies use "Comfrimation" Studys ,lmao
Especially on old worthless patents/science , new bio science is light years ahead and beyond .
rgbp--->koosimodo got da dumpster-tan face peel, i see
$RGBP $1.55 Looking for a new HOD @ $1.60 Closing strong!
$RGBP Great Interview OUT! Regen BioPharma Inc. (OTC : RGBP) is a biotechnology company. Keynote speaker: David Koos, President / CEO & Harry M. Lander, Ph.D. Senior Scientific Consultant; Regen BioPharma Inc (OTC : RGBP) Link:
What ever they are being paid, it is a waste of money because they have no effect on the share price with all of the pumping they are doing. The stock is a big pile of crap and everyone knows it I have documented for years just how corrupt the con man is and how this company is a fraud.
How much are you compensated to promote this scam this time around?
Why won't you answer this simple question?
Bidding here...
$RGBP
$RGBP "Upcoming milestones include new CRO confirmatory study results, animal studies, and an IND submission. The IND submission could lead to a Phase I clinical (human) trial in 18+ months." https://www.marketwatch.com/press-release/goldman-small-cap-research-publishes-new-research-report-on-regen-biopharma-inc-fe695ae1?mod=mw_quote_news_seemore $FSR $GOEV $GM $PHBI $BEGI $QS $F $TGGI $RDAR $AMC $GME $LCID
Should see a nice move to the 50day.
$RGBP
rgbp--->somebody scrape the barnacle off koosimodo's face please
Another Emerging Growth Train Wreck , not that BS again
The biggest problem is that with all of the blubbering form the fat bastard CEO and loser lander is that they need MONEY to further their research and they do not have that and never will.
Just listened to the CC. And it is hilarious that their test results did not provide the results they wanted. Their hypothesis was 100% wrong based on the data. It showed the opposite. What that tells you is that these clowns have no idea what they are doing as they went forward with testing thinking they knew what they had but they didn't. SO now they have to do more test to try and figure out if they can do anything with the Nerf.
The CEO also has no clue as to what he is doing. He's asking Harry how the company can pivot from small molecules to Car-T. He's the frickin CEO!
LOL
What a clown show.
$RGBP - Regen presentation archived from Emerging Growth Conference November 1, 2023
$RGBP $RGBPP
— Regen BioPharma Inc. (@TheRegenBio) November 3, 2023
Regen presentation archived from Emerging Growth Conference November 1, 2023https://t.co/idR3ZNPaWo
Yeah, I would guess so but I hoped that they'd PR about the conference and how it went.
$RGBP
The Emerging Growth presentation was yesterday. It can probably still be viewed if anybody missed it.
The company has had some great PRs over the past few weeks and I expect an update from the Emerging Growth Conference...
"We plan to use this time to discuss our most recent scientific results around our DuraCAR program as well as update our shareholders on our financial plan," says Dr. David Koos, CEO and Chairman of the Company.
$RGBP
$RGBP Oct. 25, 2023 9:30 AM ET -Regen BioPharma, Inc. PFD SER A NEW (RGBPP), RGBP
Autoimmunity to be Targeted
SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html) while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html.
Very promising News...
"Being able to substantially elevate NR2F6 levels is truly an unexpected, but welcome finding. We now have a sound scientific basis to pursue designing T cells which can tamp down on the uncontrolled immune activation seen in multiple autoimmune disorders," says Dr. Harry Lander, Chief Scientific Consultant to the Company. "We recently filed a patent application around such T cells and we feel we have a head start on this in the scientific community, particularly around using nuclear receptors such as NR2F6."
$RGBP
Apparently not enough as the clown posse hasn't been able to pump the share price at all. Looks like some are going to get fired soon. Lol
How much are you being compensated to promote this stock?
You state publicly that you are compensated to promote stocks, yet refuse to answer how much this compensation is.
Why is that?
Looking forward to seeing an update from the conference within the next few days.
$RGBP
The clinical results data that RGBP now has in hand from confirming sources demonstrate that there is great potential in the company's approach.
The Company has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments. These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA. NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression.
Yes, the market is liking what RGBP has to say now and what is in development. Additionally, the Federal Reserve held even on interest rates again today which is good for the market in general. As we go forward the table is set here for pps appreciation.
$RGBP bullish move with today's presentation!
RGBP has a strong developing story in the emerging fields of advanced cancer treatments and for other important diseases.
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available athttp://www.regenbiopharmainc.com.
Very good to see RGBP management directly presenting at the important investor conference today. This is the best way to get a company's progress into the spotlight for everyone to review.
Regena BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023 https://finance.yahoo.com/news/regen-biopharma-inc-discuss-confirmation-133000016.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$RGBP Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now
https://goto.webcasts.com/starthere.jsp?ei=1603286&tp_key=f701725cb0&sti=globe
Have not been here for a long time.. Wow ,what a disaster after the reverse split... Most happy I sold my shares prior.
rgbp--->crust-face_koosimodo_gonga_save_du_world("du"_for_dumpster)
Hey, Fatman and Robbing will again present at that bogus Emerging Conmen conference on the 1st. It is always a blast to hear Dumbass Dave sputter and tell us nothing and to watch Harry Flander nod off on screen.
OMG! THIS IS HUGE! THE KONMAN KOOS IS GOING TO..WAIT FOR IT...WAIT FOR IT....TALK ABOUT WHAT WAS SAID IN THE PR ABOUT CONFIRMATORY ROUTINE LAB RESULTS THAT PROVE NOTHING OTHER THAN IT THEY WERE ABLE TO DUPLICATE A SIMPLE IN VITRO LAB RESULT! THIS SHOULD SURELY MAKE THE STOCK POP TO AT LEAST $5!
BTW, DID YOU SEE THE NEWS ON REGEN'S "BIG PHARMA" PARTNER ONCOLOGY PHARMA?
$RGBP NEWS! @TheRegenBio Regena BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023 https://finance.yahoo.com/news/regen-biopharma-inc-discuss-confirmation-133000016.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance @frontpagestocks
Taking about "right decisions," how did the right decisions about the reverse split work out for the pathetic lying piece of crap CEO?
Also remember that the scumbag CEO who lies through his veneers that hide his rotten teeth and paid his brother $319K to do absolutely nothing was supposed to focus on DouchbagCellVax. These typical preclinical lab tests prove absolutely nothing about Nerf. And what is the pIt willan now for nerf? No one is going to give the fat bastard money. NERF will die on the vine just line HemaX and DcellVax.
What's funny is how old is NR2F6 , and in the article there using "unexpected and potentially extremely useful findings" , oh OK .
Second Confirmatory - I'm crying laughing
"Having a second confirmatory study gives us confidence we are making the right decision to pursue these novel cell therapies focused on autoimmunity," says Dr. David Koos, Chairman and CEO of the company. "I expect that after consulting with our Board of Advisors and internally, the Company will soon have a clear picture of the specific indications and approaches it will pursue."
$RGBP
New posters yet with the same pump. Some things never change on this clown show website
But the Koos klown posse are telling us this is the real deal for the millionth time in over a decade? Are you sure it isn’t for realsie THIS time around?
Hilarious , "Confirmatory and unexpected " lol . This Clown has no shame , and It's impressive how long he's been riding the NR2F6 train . Compared to other biotech's IP's this "science" is outdated at best . Dont take my word for it -Research it , even the Nasdaq delinquent company's have more credibility and actual phase trials underway . Koo's really is a conman , spinning the crap anyway he can . Flip it , make some money if possible , don't fall for the BS tho . Been there , done that .
This is HUGE News...
The Company has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments. These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA. NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression.
$RGBP
WOW! HUGE NEWS! THIS SHOULD POP TO $2 JUST ON THIS CONFIRMATORY NEWS ALONE BECAUSE IT MEANS REGEN HAS CURED CANCER! AND THIS NEWS WILL MEAN KOOSIE WILL GET THAT FUNDING HE WAS PROMISED BUT DIDN'T GET AFTER THE REVERSE SPLIT, RIGHT?
The Company has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments. These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA. NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression.
$RGBP
Couscous is a crook and an inveterate liar who has in the past killed several companies. You have to be stupid to still believe this big pig who puts out bogus PRs for naive and gullible traders.....LOOOOL !!!
Followers
|
1052
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
118384
|
Created
|
09/03/14
|
Type
|
Free
|
Moderators Huggy Bear SmellMyFinger |
0.000x Ticker Symbol: RGBP
Barchart
All other Regen BioPharma News
https://www.regenbiopharmainc.com/company-news.html
Date | Outsanding Shares | Reason for Issue |
---|---|---|
12/31/21 | 4,564,002,832 | |
3/28/22 | 4,580,002,832 | Debt and Interest |
4/7/22 | 4,736,002,832 | Debt and Interest |
5/16/22 | 4,820,002,832 | Debt |
7/1/22 | 4,920,002,832 | Debt |
7/17/22 | 4,970,002,832 | Debt and Interest |
8/1/22 | 5,024,517,324 | Debt |
8/4/22 | 5,031,517,324 | EXPENSES |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |